US Food and Drug Administration (FDA) in a calendar year, with this year set to break this record again, analysis suggests.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded the US out of hundreds of millions of dollars.

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

The introduction of the first-generation anti-VEGF drugs—Macugen (pegaptanib), Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab)—has since been followed by longer-lasting agents ...